Carfilzomib‐based antibody mediated rejection therapy in pediatric kidney transplant recipients
Pediatric Transplantation · 2023
DOI: 10.1111/petr.14534 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Transplantation, 2023. Verfasst von Ellen M Cody und 6 weiteren Autor:innen. Beteiligte Einrichtung: Divison of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Oligopeptides, Proteasome Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
To date, the evidence for proteasome‐inhibitor (PI) based antibody mediated rejection (AMR) therapy has been with the first‐generation PI bortezomib. Results have demonstrated encouraging efficacy for early AMR with lesser efficacy for late AMR. Unfortunately, bortezomib is associated with dose‐limiting adverse effects in some patients. We report use of the second generation proteosome inhibitor carfilzomib for AMR treatment in two pediatric patients with a kidney transplant.
Methods
The clinical data on two patients who experienced dose limiting toxicities from bortezomib were collected along with their short‐ and long‐term outcomes.
Results
A two‐year‐old female with simultaneous AMR, multiple de novo DSAs (DR53 MFI 3900, DQ9 MFI 6600, DR15 2200, DR51 MFI 1900) and T‐cell mediated rejection (TCMR) completed three carfilzomib cycles and experienced stage 1 acute kidney injury after the first two cycles. At 1 year follow up, all DSAs resolved, and her kidney function returned to baseline without recurrence. A 17‐year‐old female also developed AMR with multiple de novo DSAs (DQ5 MFI 9900, DQ6 MFI 9800, DQA*01 MFI 9900). She completed two carfilzomib cycles, which were associated with acute kidney injury. She had resolution of rejection on biopsy and decreased but persistent DSAs on follow‐up.
Conclusions
Carfilzomib treatment for bortezomib‐refractory rejection and/or bortezomib toxicity may provide DSA elimination or reduction, but also appears to be associated with nephrotoxicity. Clinical development of carfilzomib for AMR will require a better understanding of efficacy and development of approaches to mitigate nephrotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Divison of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.
- James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pathology, University of Cincinnati, Cincinnati, Ohio, USA.
ORCID-Profile: Ellen M Cody, Charles Varnell, Danielle Lazear, E Steve Woodle, David K Hooper
Zitieren
APA
Cody, E. M., Varnell, C., Lazear, D., VandenHeuvel, K., Flores, F. X., Woodle, E. S., & Hooper, D. K. (2023). Carfilzomib‐based antibody mediated rejection therapy in pediatric kidney transplant recipients. Pediatric Transplantation. https://doi.org/10.1111/petr.14534
Vancouver
Cody EM, Varnell C, Lazear D, VandenHeuvel K, Flores FX, Woodle ES, et al. Carfilzomib‐based antibody mediated rejection therapy in pediatric kidney transplant recipients. Pediatric Transplantation. 2023. doi:10.1111/petr.14534
BibTeX
@article{Cody2023,
author = {Cody, Ellen M and Varnell, Charles and Lazear, Danielle and VandenHeuvel, Katherine and Flores, Francisco X and Woodle, E Steve and Hooper, David K},
title = {Carfilzomib‐based antibody mediated rejection therapy in pediatric kidney transplant recipients},
journal = {Pediatric Transplantation},
year = {2023},
doi = {10.1111/petr.14534}
}
EUVIMED